A Theoretical Study on Inhibition of Melanoma with Controlled and Targeted Delivery of siRNA via Skin Using SPACE-EGF
- 257 Downloads
Melanoma is a potentially lethal skin cancer with high mortality rate. Recently, the peptide-mediated transdermal delivery of small interference RNA (siRNA) emerges as a promising strategy to treat melanoma by inducing the apoptosis of tumor cells, but the related theoretical model describing the delivery of siRNA under the effect of SPACE-EGF, the growth inhibition of melanoma and the dynamic expanding of the bump on the skin due to the growth of melanoma has not been reported yet. In this article, a theoretical model is developed to describe the percutaneous siRNA delivery mediated by SPACE-EGF to melanoma and the growth inhibition of melanoma. The results present the spatial–temporal distribution of siRNA and the growth of melanoma under the inhibition of siRNA, which shows a good consistency with the experimental results. In addition, this model represents the uplift process of tumors on the skin surface. The model presented here is a useful tool to understand the whole process of the SPACE-EGF-mediated delivery of the siRNA to melanoma through skin, to predict the therapeutic effect, and to optimize the therapeutic strategy, providing valuable references for the treatment of melanoma.
KeywordsMelanoma siRNA Peptide carrier Tumor growth inhibition Transdermal drug delivery
This work was supported partly by the Specialized Research Fund for the Doctoral Program of Higher Education of China (20133402120033), the National Natural Science Foundation of China (81571768, 81627806), and the Natural Science Foundation of Anhui Province (1408085ME96). We would like to thank Research Center for Life Sciences at the University of Science and Technology of China for assistance.
J.L. and W.D. developed the theoretical model. J.L. accomplished the numerical simulation and data analysis. R.R, W.D., M.C. and L.W. designed the experiments. R.R., L.Z., M.C. and P.W. conducted the experiments. J.L. wrote the manuscript with inputs from all co-authors. All authors reviewed the manuscript.
Conflict of interest
The authors declare no competing financial interests.
- 4.Bartlett, D. W., H. Su, I. J. Hildebrandt, W. A. Weber, and M. E. Davis. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. USA 104:15549–15554, 2007.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Desai, P. R., S. Marepally, A. R. Patel, C. Voshavar, A. Chaudhuri, and M. Singh. Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J. Control. Release 170:51–63, 2013.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Graff, C. P., and K. D. Wittrup. Theoretical analysis of antibody targeting of tumor spheroids importance of dosage for penetration, and affinity for retention. Can. Res. 63:1288–1296, 2003.Google Scholar
- 39.Leachman, S. A., R. P. Hickerson, M. E. Schwartz, E. E. Bullough, S. L. Hutcherson, K. M. Boucher, C. D. Hansen, M. J. Eliason, G. S. Srivatsa, D. J. Kornbrust, F. J. D. Smith, W. H. I. McLean, L. M. Milstone, and R. L. Kaspar. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol. Ther. 18:442–446, 2010.CrossRefPubMedGoogle Scholar
- 50.Rao, Y.-F., W. Chen, X.-G. Liang, Y.-Z. Huang, J. Miao, L. Liu, Y. Lou, X.-G. Zhang, B. Wang, R.-K. Tang, Z. Chen, and X.-Y. Lu. Epirubicin-loaded superparamagnetic iron-oxide nanoparticles for transdermal delivery: cancer therapy by circumventing the skin barrier. Small 11:239–247, 2015.CrossRefPubMedGoogle Scholar
- 53.Shenenberger, D. W. Cutaneous malignant melanoma: a primary care perspective. Am. Fam. Phys. 85:161–168, 2012.Google Scholar
- 61.Zheng, D., D. A. Giljohann, D. L. Chen, M. D. Massich, X.-Q. Wang, H. Iordanov, C. A. Mirkin, and A. S. Paller. Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc. Natl. Acad. Sci. USA 109:11975–11980, 2012.CrossRefPubMedPubMedCentralGoogle Scholar
- 62.Zhuang, D., S. Mannava, V. Grachtchouk, W. H. Tang, S. Patil, J. A. Wawrzyniak, A. E. Berman, T. J. Giordano, E. V. Prochownik, M. S. Soengas, and M. A. Nikiforov. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 27:6623–6634, 2008.CrossRefPubMedGoogle Scholar